CASE REPORT |
|
Year : 2016 | Volume
: 2
| Issue : 2 | Page : 102-104 |
|
Sorafenib-induced pemphigus vulgaris
Ajay Deshpande
Department of Dermatology, Maharashtra Medical Foundation, Joshi Hospital, Pune, Maharashtra, India
Correspondence Address:
Ajay Deshpande Maharashtra Medical Foundation, Joshi Hospital, 777, Shivaji Nagar, Pune - 411 004, Maharashtra India
Source of Support: None, Conflict of Interest: None | Check |
DOI: 10.4103/2455-3972.196172
|
|
Sorafenib is a tyrosine kinase inhibitor approved for the treatment of primary kidney cancer, advanced primary hepatocellular carcinoma and radioactive iodine-resistant advanced thyroid carcinoma. Sorafenib is known to cause milder cutaneous side effects such as maculopapular rash and serious cutaneous drug reactions such as desquamation of the skin, hand-foot syndrome Stevens-Johnsons syndrome and toxic epidermal necrolysis. We report a histopathologicaly proved case of pemphigus vulgaris caused by sorafenib. |
|
|
|
[FULL TEXT] [PDF]* |
|
|
|